{"id":"NCT00770146","sponsor":"Kastle Therapeutics, LLC","briefTitle":"Safety and Efficacy of Mipomersen (ISIS 301012) As Add-on Therapy in High Risk Hypercholesterolemic Patients","officialTitle":"A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety and Efficacy of ISIS 301012 (Mipomersen) as Add-on Therapy in High Risk Hypercholesterolemic Patients","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2008-11","primaryCompletion":"2010-05","completion":"2010-10","firstPosted":"2008-10-09","resultsPosted":"2013-03-20","lastUpdate":"2016-09-09"},"enrollment":158,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Hypercholesterolemia","Coronary Heart Disease"],"interventions":[{"type":"DRUG","name":"Mipomersen sodium","otherNames":["ISIS 301012","Kynamroâ„¢"]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"Placebo","type":"PLACEBO_COMPARATOR"},{"label":"Mipomersen","type":"EXPERIMENTAL"}],"summary":"The purpose of this study is to evaluate the safety and efficacy of dosing with mipomersen for 26 weeks in patients with high cholesterol who are on a maximally tolerated dose of statin and who have a diagnosis that puts them at least at high risk of coronary heart disease (CHD).","primaryOutcome":{"measure":"Percent Change From Baseline in Low-density Lipoprotein Cholesterol (LDL-C) at the Primary Efficacy Time Point","timeFrame":"Baseline (the average of the screening and Day 1 pre-treatment assessments) and the Primary Efficacy Time point (PET; Week 28 or the post-baseline visit closest to 14 days after the last dose).","effectByArm":[{"arm":"Placebo","deltaMin":-3.4,"sd":24.22},{"arm":"Mipomersen","deltaMin":-40.2,"sd":26.85}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.001"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":5,"exclusionCount":1},"locations":{"siteCount":62,"countries":["United States"]},"refs":{"pmids":["25614280","24013058"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":4,"n":52},"commonTop":["Injection site pain","Injection site erythema","Injection site pruritus","Injection site discolouration","Injection site haematoma"]}}